INVESTOR ALERT: Class Action Lawsuit Against The Medicines Company Announced by Glancy Binkow & Goldberg LLP
Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed on behalf of all purchasers of the securities of The Medicines Company (NASDAQ:MDCO) between February 20, 2013 and February 12, 2014, inclusive (the “Class Period”). If you purchased The Medicines Company shares during the Class Period, please contact us toll-free at (888) 773-9224, or at (212) 682-5340, or by email to email@example.com to discuss this matter.
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The Company’s products include anticoagulants and treatments for blood pressure control and other cardiovascular indications. The complaint, filed in the United States District Court for the District of New Jersey, alleges violations of federal securities laws and that:
- The Medicines Company issued materially misleading statements concerning the efficacy of its drug candidate Cangrelor, for preventing blood clots during angioplasty and stenting procedures, when compared to clopidogrel – a competing, FDA-approved drug.
- The Company failed to disclose that the CHAMPION clinical trials of Cangrelor were unethically and inappropriately administered.
On February 13, 2014, the price of The Medicines Company shares dropped more than 11% after the Company announced that the Food and Drug Administration’s Cardiovascular and Renal Drugs Advisory Committee voted against approval of Cangrelor for patients undergoing certain cardiac procedures.
If you are a member of the Class described above, you may move the Court no later than April 22, 2014, to serve as lead plaintiff. If you wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340 or 888-773-9224